Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: Patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial

Annals of the Rheumatic Diseases

Volumn 66, Issue 2, 2007, Pages 163-168

  Gladman, D D ^a,b   Mease, P J ^c   Cifaldi, M A ^d   Perdok, R J ^d   Sasso, E ^d   Medich, J ^d  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 36; SOCIAL STATUS; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EUROPE; FATIGUE; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PAIN; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SKIN; TREATMENT OUTCOME; UNITED STATES;

EID: 33846871057     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.057901     Document Type: Article

References (40)

1. Mease PJ. Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002;61:298-304.
2. Winterfield LS, Meneter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64:87-90.
3. Gladman DD. Quality of life: psoriatic arthritis. In: Gordon KB, Ruderman EM, eds. Psoriasis and psoriatic arthritis: an integrated approach. Heidelberg, Germany: Springer, 2004:118-23.
4. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PsA) _ an analysis of 220 patients. QJM 1987;62:127-41.
5. Hahn HB, Melfi CA, Chuang TY, Lewis CW, Gonin R, Hanna MP, et al. Use of the Dermatology Life Quality Index (DLQI) in a Midwestern US urban clinic. J Am Acad Dermatol 2001;45:44-8.
6. Torre Alonso JC, Rodriguez PA, Arribas Castrillo JM, Ballina Garcia J. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50.
7. Wong K, Gladman DD, Husted J, Long J, Farewell VT. Mortality studies in psoriatic arthritis. Arthritis Rheum 1997;40:1868-72.
8. Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850-60.
9. Mau W, Listing J, Huscher D, Zeidler H, Zink A. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005;32:721-8.
10. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl II):ii14-17.
11. Gladman DD. Discussion: clinical features, epidemiology, classification criteria, and quality of life in psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl II):ii24-5.
12. Husted JA, Gladman DD, Farewell VT, Long JA, Cook RJ. Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997;24:511-17.
13. Zachariae H, Zachariae R, Blomqvist K, Davidsson S, Molin L, Mork C, et al. Quality of life and prevalence of arthritis reported by 5795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-13.
14. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
15. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Invest Drugs 2000;9:1511-22.
16. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life in patients with psoriatic arthritis. A comparison with patients with rheumatoid arthritis. Arthritis Care Res 2001;45:151-8.
17. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. Arthritis Rheum 2005;53:404-9.
18. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001;28:1842-6.
19. Rahman P, Nguyen E, Cheung C, Schentag CT, Gladman DD. Comparison of radiological severity in psoriatic arthritis and rheumatoid arthritis. J Rheumatol 2001;28:1041-4.
20. Husted JA, Gladman DD, Long JA, Farewell VT. A modified version of the health assessment questionnaire (HAQ). Clin Exp Rheumatol 1995;13:439-43.
21. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T et al. Epidemiology of psoriatic arthritis in the United States population. J Am Acad Dermatol 2005;53:573.
22. Mease PJ, Gladman DD, Ritchlin CT, for the ADEPT Study Group. Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: results of ADEPT. Arthritis Rheum 2005;52:3279-89.
23. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the Health Assessment Questionnaire, Disability and Pain scales. J Rheumatol 1982;9:789-93.
24. Husted JA, Gladman DD, Cook PJ, Farewell VT. Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998;25:2146-55.
25. Mease PJ, Ganguly R, Wanke L, Yu E, Singh A. How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) group guidelines [abstract]. Ann Rheum Dis 2004;63(Suppl 1):391.
26. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl II):ii49-54.
27. Ware JE Jr, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-83.
28. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey. Manual and interpretation guide. Lincoln, RI: QualityMetric, 2002.
29. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
30. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. J Rheumotol 2005;32:811-19.
31. Cella D, Lai J-S, Chang C, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-38.
32. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 1997;13:63-74.
33. Chandran V, Bhella S, Schentag T, Gladman DD. The FACIT-Fatigue scale is valid in patients with psoriatic arthritis (PsA). Arthritis Rheum 2005;52:4084.
34. Finlay AY, Khan GK. Dermatology life quality index (DLQI)_a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
35. Zachariae R, Zachariae C, Ibsen H, Mortensen JT, Wulf HC. Dermatology Life Qualify Index: data from Danish inpatients and outpatients. Acta Derm Venereol 2000;80:272-6.
36. Mork C, Wahl A, Moum T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics. Acta Derm Venereol 2002;82:347-51.
37. Badia X, Mascaro JM, Lozano R. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to the DLQI. Br J Dermatol 1999;141:698-702.
38. Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. Br J Dermatol 2002; 147(Suppl 62):50.
39. Feldman SR, Kimball AB, Krueger GG, Woolley JM, Lalla D, Jahreis A. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-9.
40. Melilli L, Shikiar R, Thompson C. Minimum clinically important difference in Dermatology Life Quality Index in moderate to severe plaque psoriasis patients treated with adalimumab. J Am Acad Dermatol 2006;54(Suppl):AB221.